@vrs37 - you posted that "from what I can see their trial shares lot of similarity with dmx fgs phase 3 trial, like the same endpoints and length"
This is a very different view than that articulated in a recent Investor Presentation in a DXB announcement - where they claimed there is NO comparison with Travere's Duplex trial (see slide below).
I like contrary views that are based on science and logical argument, but I don't like manipulative innuendo.
While not, at this moment, accusing you of the latter, I would like to see your more detailed arguments as to why you are correct and why Dimerix management is not. Unsubstantiated statements or inferences are completely worthless!
DXB Price at posting:
14.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)